Bevacizumab as Treatment for Patients With Relapsed/Refractory Multiple Myeloma

Trial Profile

Bevacizumab as Treatment for Patients With Relapsed/Refractory Multiple Myeloma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2014

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 05 Mar 2014 New source identified and integrated (ClinicalTrials.gov; NCT02079519).
    • 18 Apr 2009 Status changed from recruiting to discontinued as reported by Roche.
    • 06 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top